AbCellera Biologics Inc. Revenue 2019–2025
AbCellera Biologics Inc. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- AbCellera Biologics Inc. revenue for the quarter ending March 31, 2026 was 8.3 M, a 96.34% increase year-over-year.
- AbCellera Biologics Inc. revenue for the twelve months ending March 31, 2026 was 38.6 M, a 27.01% increase year-over-year.
- AbCellera Biologics Inc. annual revenue for 2025 was 75.1 M, a 160.56% increase from 2024.
- AbCellera Biologics Inc. annual revenue for 2024 was 28.8 M, a 24.17% decrease from 2023.
- AbCellera Biologics Inc. annual revenue for 2023 was 38.0 M, a 92.17% decrease from 2022.
- AbCellera Biologics Inc. annual revenue for 2022 was 485.4 M.
AbCellera Biologics Inc. (ABCL) — Frequently Asked Questions
AbCellera Biologics Inc. (ABCL) is a publicly traded US company. It has a market capitalization of $1.52B. In fiscal 2025 it reported revenue of $75M and net income of -$146M. Explore ABCL's stock price, financial statements, earnings history, margins and key ratios below.
What is AbCellera Biologics Inc.'s market cap?
AbCellera Biologics Inc. (ABCL) has a market capitalization of $1.52B.
What is the ABCL stock price?
ABCL trades at $5.09 (-3.96% on the day).
How much revenue does AbCellera Biologics Inc. make?
AbCellera Biologics Inc. reported revenue of $75M in fiscal 2025.
Is ABCL profitable?
In fiscal 2025, AbCellera Biologics Inc. reported net income of -$146M.